United Therapeutics reports record $2.88B revenue in FY2024, up 24% YoY

UNITED THERAPEUTICS Corp

2024-FY EPS reported $24.64 revenue$2,877,400,000

Q4 revenue $735.9M (+20% YoY); net income $301.3M vs $217.1M in Q4 2023.
Full-year net income $1.195B ($24.64 diluted EPS) vs $984.8M in 2023 (diluted EPS $19.81).
Tyvaso franchise revenue grew 31% to $1.62B in 2024, driven by Tyvaso DPI (up 41%).
Completed $1B accelerated share repurchase, repurchasing ~3.55M shares.
Recorded $71.1M litigation accrual for Sandoz; R&D expense up 18% on organ projects.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.